- Conditions
- Acute Myeloid Leukemia
- Interventions
- Venetoclax, Revumenib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1993–2016
of 5,570
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections
- Interventions
- Delavirdine mesylate
- Drug
- Lead sponsor
- Pharmacia and Upjohn
- Industry
- Eligibility
- 1 Month to 15 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Peapack, New Jersey
- Conditions
- Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo, Gem-Cis or Gem-Carbo
- Device · Drug
- Lead sponsor
- Robert C. Martin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- NSCLC Stage IV
- Interventions
- AB-16B5, Docetaxel
- Drug
- Lead sponsor
- Alethia Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Stroke
- Interventions
- Actuated Virtual Keyboard (AVK) system, Occupational Therapy (OT)
- Behavioral
- Lead sponsor
- North Carolina State University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Raleigh, North Carolina
- Conditions
- Esophageal Cancer
- Interventions
- bevacizumab, cisplatin, irinotecan hydrochloride, proteomic profiling, diagnostic laboratory biomarker analysis, mass spectrometry, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy
- Biological · Drug · Genetic + 3 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Cancer, Metastatic Cancer
- Interventions
- Mocaciclib (Q901), KEYTRUDA® (pembrolizumab), Fulvestrant
- Drug
- Lead sponsor
- Qurient Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
- Conditions
- Parkinson's Disease
- Interventions
- CD-LD IR, IPX203 180 mg, IPX203 270 mg, Rytary 195 mg, Rytary 145 mg
- Drug
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 8 more
- Conditions
- Metastatic Cancer, Cancer, Solid Tumor
- Interventions
- BP31510 monotherapy, BP31510 in combination with chemotherapy
- Drug
- Lead sponsor
- BPGbio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 3
- States / cities
- Sunnyvale, California • New York, New York • Houston, Texas
- Conditions
- Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Interventions
- Fam-Trastuzumab Deruxtecan-Nxki
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- ASTX727
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer
- Interventions
- favezelimab/pembrolizumab, regorafenib, TAS-102
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 441 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 15
- States / cities
- Washington D.C., District of Columbia • Marietta, Georgia • Louisville, Kentucky + 11 more
- Conditions
- Low Milk Supply, Pre-diabetes, Insulin Resistance, Suppressed Lactation
- Interventions
- Standard care, Metformin, Placebo
- Behavioral · Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 20 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Solid Tumors
- Interventions
- Runimotamab, Trastuzumab, Tocilizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Saint Louis, Michigan • New York, New York + 2 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- High-dose chemotherapy
- Procedure
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1987 – 2002
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
- Interventions
- denintuzumab mafodotin, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Duarte, California + 31 more
- Conditions
- Metastatic Urothelial Cancer
- Interventions
- Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Avelumab, Zimberelimab, Carboplatin, Gemcitabine, Domvanalimab, Enfortumab Vedotin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 30
- States / cities
- Tucson, Arizona • San Francisco, California • Littleton, Colorado + 25 more
- Conditions
- Breast Cancer
- Interventions
- TAK-228, Letrozole
- Drug
- Lead sponsor
- Gary Schwartz
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Acute Respiratory Failure
- Interventions
- IV amino acids, In-bed cycle ergometry exercise
- Drug · Device
- Lead sponsor
- Clinical Evaluation Research Unit at Kingston General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 7
- States / cities
- Lexington, Kentucky • Baltimore, Maryland • The Bronx, New York + 4 more
- Conditions
- Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular T-Cell Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
- Interventions
- Brentuximab Vedotin, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Cognitive Behavioral Therapy, Motivational Interviewing, FDA-Approved Anti-Anxiety Medications, Standard Care Control
- Behavioral · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Malignant Glioma, Glioblastoma
- Interventions
- MRZ, BEV
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 4
- States / cities
- Orange, California • Santa Monica, California • New York, New York + 1 more
- Conditions
- Advanced Solid Tumor
- Interventions
- BG-C9074, Tislelizumab, Bevacizumab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • Orlando, Florida + 2 more
- Conditions
- Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
- Interventions
- Maplirpacept (PF-07901801), Azacitidine, Venetoclax, Carfilzomib, Dexamethasone, Anti-CD20 Targeting agent, Isatuximab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 62
- States / cities
- Los Angeles, California • Pasadena, California • Denver, Colorado + 29 more